In recent years, several studies have been performed to analyse the causes of chronic leg ulcers in young men with Klinefelter's syndrome. It is well known that leg ulcers, especially in combination with hyperpigmentation, are common symptoms of this chromosomal abnormality, with a prevalence of up to 13% in one series of 150 patients. 1, 2 These patients, however, often lack a history of deep venous thrombosis or signs of chronic venous insufficiency which could explain the ulceration. 3, 4 Abnormalities in fibrinolysis, as documented by elevated plasminogen activator inhibitor-1 (PAI-1) activity levels, have been observed, and are thought to be the cause of ulceration. [5] [6] [7] However, interpretation of PAI-1 levels has to be performed very carefully since several disease states and living conditions are known to influence PAI-1 activity. These include diabetes mellitus, arterial hypertension, hypertriglyceridaemia, smoking and physical activity. [8] [9] [10] [11] [12] Furthermore, PAI-1 correlates positively with the body mass index (BMI; weight/ height 2 ) and acute phase proteins, and correlates negatively with testosterone levels. 8, 10, 11, [13] [14] [15] Since patients suffering from Klinefelter's syndrome are characterized by eunuchoid body proportions, i.e. a high BMI, and a low testosterone level, PAI-1 levels in patients suffering from Klinefelter's syndrome should not be compared with healthy controls or with patients suffering from chronic venous insufficiency complicated by leg ulcers. Therefore, the present study was performed to analyse PAI-1 influencing parameters and PAI-1 activity in two groups of patients: group 1 consisting of patients suffering from Klinefelter's syndrome complicated by leg ulcers (n ¼ 7) and group 2 of patients with Klinefelter's syndrome but without leg ulcers (n ¼ 6). The aims of the study were to find out whether (i) PAI-1 activity is elevated in Klinefelter's syndrome in general; and (ii) whether PAI-1 elevation in patients suffering from Klinefelter's syndrome is due to PAI-1 influencing parameters. In addition, by comparing PAI-1 influencing parameters and PAI-1 activity in group 1 and 2 patients, we wanted to find out whether PAI-1 activity is intimately involved in leg ulceration in Klinefelter patients.
Material and methods

Patients
Two patients (numbers 1 and 2) suffering from Klinefelter's syndrome complicated by leg ulcers and five other (numbers 3-7) patients documented earlier [5] [6] [7] were analysed. The characteristics of these patients are listed in Table 1 . Furthermore, six patients (numbers 8-13) with previously unknown Klinefelter's syndrome without leg ulcers, served as disease-matched controls ( Table 2) .
Determination of haemostatic and fibrinolytic parameters
In patients 3-7, the parameters were analysed as documented earlier. [5] [6] [7] In the other patients (1, 2 and 8-13), t-PA-Ag and PAI-1 antigen were determined by an enzyme-linked immunosorbent assay using TintElize PAI-1 (PAI-1 antigen; Biopool, Malmö, Sweden) and TintElize-TPAg (tPA-Ag; Biopool), respectively. 16 PAI-1 activity in sodium citrate plasma samples was determined using Spectrolyse pL PAI-1 (PAI-1 activity; Biopool).
Statistical analysis
Statistical comparisons were made using the WilcoxonMann-Whitney test for quantitative parameters with the BiAS . 5 . 01 computer program (H.Ackermann, Frankfurt, Germany). For non-quantitative parameters, the Fisher test was used. Differences between groups were considered significant at P < 0 : 05.
Case reports
Two patients with a long-standing history of ulceration on both legs were admitted. In both, there was no history of thromboembolic disease, arterial occlusive disease or diabetes mellitus. Patient 2 suffered from arterial hypertension which was treated with a combination of hydrochlorothiazide and triamterene. Furthermore, both patients had been smokers for several years. Both were tall and obese with a BMI of 29·1 kg/m 2 and 34·1 kg/m 2 , respectively. Karyotype analysis in patient 1 revealed 47,XXY and, in patient 2, 47,XXY, inv(9) (p13·1-q21·2). Prior to laboratory tests, the patients did not receive any therapy influencing fibrinolytic parameters. The results of the analysis of fibrinolytic parameters and PAI-1 influencing parameters are listed in Table 1 Own patients Hesse et al. 5 Veraart et al. 6 Pernod et al. 29·1  34·1  18·5  23·4  28·7  22·1  44·3  Triglyceride  1·79  1·69  2·7  4·4  2·07  NA  2·09  C-reactive protein  6  6  NA  NA  NA  NA  < 6  Fibrinogen  3·2  5·2  3·19  4·48  2·8  3·2  3·2  Testosterone  9·1  4·6  11·7  8·3  10  15  6·2  PAI-1 activity  16·4  28·1  21  33·5  22  23  17  t-PA  9·8  NA  7·4  9·9  8·5  30  8·7 AOD, arterial occlusive disease; CVI, chronic venous insufficiency; BMI, body mass index (kg/m 2 ); NA, not analysed. Triglyceride (mmol/l); C-reactive protein (mg/l); fibrinogen (g/l); testosterone (total) (nmol/l); PAI-1 activity (U/ml); t-PA (U/ml).
The clinical data of patients suffering from Klinefelter's syndrome, which was not complicated by leg ulcers are listed in Table 2 . These patients were admitted between 1994 and 1996 for male infertility. None suffered from diabetes mellitus, arterial occlusive disease or thromboembolic disease. Two of the six were smokers. One patient (number 11) had a history of arterial hypertension which was treated with a betablocker. The patients had elevated BMI and other typical signs of Klinefelter's syndrome. In all cases, the clinical diagnosis of Klinefelter's syndrome was confirmed by karyotype analysis. None had received therapy with an impact on fibrinolysis. PAI-1 activity was in the upper normal range in four of the six patients and slightly elevated in two who had very high BMI (patients10 and 11).
Results
In Table 1 , parameters influencing PAI-1 activity are listed and the clinical and laboratory data of seven patients are summarized. In Table 2 , the characteristics of a second group of patients suffering from Klinefelter's syndrome not complicated by leg ulceration are given. PAI-1 influencing parameters were analysed in both groups. No significant differences were found when comparing the parameters of these two groups using the Wilcoxon-Mann-Whitney test (i.e. age, BMI, triglyceride, fibrinogen, and testosterone) and the Fisher test (for smoking, diabetes mellitus, arterial hypertension, and arterial occlusive disease), respectively. This clearly indicates that the two groups did not differ significantly regarding parameters with impact on PAI-1. However, highly significant differences between the two groups were observed when comparing PAI-1 activity (P ¼ 0 : 0016).
Discussion
Fibrinolysis is regulated by the precise counterplay of plasminogen activators, such as urokinase and tissueplasminogen activator (t-PA), and PAI. PAI binds irreversibly to these plasminogen activators, thus inactivating fibrinolytic activity of plasminogen activators. Deficient fibrinolysis in blood contributes to the development of venous as well as arterial thrombosis. [17] [18] [19] Therefore, a defective fibrinolysis might be involved in the pathogenesis of chronic leg ulceration. Indeed, a reduced periulcerous endothelial release of t-PA has been shown recently. 20 In addition, pronounced expression of PAI-1 at the edges of experimental wounds has been documented. 21 Furthermore, in lipodermatosclerosis, underlying venous insufficiency significantly increased PAI-1 activity compared to a control group. ). Triglyceride (mmol/l); C-reactive protein (mg/l); fibrinogen (g/l); testosterone (total) (nmol/l); PAI-1 activity (U/ml); t-PA (U/ml). * Results were regarded as significant if P < 0 : 05 when comparing patients of group 1 with patients of group 2 using the Wilcoxon-Mann-Whitney test or the Fisher test, respectively.
† Wilcoxon-Mann-Whitney test. ‡ Fisher test.
hampering the interpretation of the data. In another study analysing patients suffering from leg ulcers caused by chronic venous insufficiency, no significant changes in the parameters of fibrinolytic activity were observed 16 indicating that the analysis of fibrinolytic abnormalities in chronic venous insufficiency is still a matter of debate. In cases of leg ulceration associated with Klinefelter's syndrome, there are several reports which document an increased PAI-1 activity. [5] [6] [7] This supports a potential role for PAI-1 activity. PAI-1 activity is increased in several conditions typically associated with Klinefelter's syndrome, such as obesity, high BMI, and reduced testosterone concentration. Therefore, PAI-1 activity levels in Klinefelter patients should not be compared with healthy controls or patients with venous insufficiency, but with Klinefelter patients without leg ulceration, as they should match better regarding the parameters which influence PAI-1. Therefore, we compared PAI-1 activity in patients suffering from Klinefelter's syndrome complicated by leg ulcers (group 1) with another group of Klinefelter patients without leg ulceration (group 2). Comparison of these two groups regarding parameters with known impact on PAI-1 revealed no significant differences in these two groups. However, PAI-1 activity in group 1 was significantly higher (P < 0 : 005) than in group 2. This clearly excludes the possibility that elevated PAI-1 activity in Klinefelter's syndrome complicated by leg ulcers is associated with Klinefelter's syndrome itself or with associated disorders such as a low serum testosterone or a high BMI.
Since we have demonstrated that increased PAI-1 activity in group 1 patients is not due to PAI-1 influencing parameters, we suggest that PAI-1 is intimately involved in the pathogenesis of leg ulceration in Klinefelter's syndrome. Furthermore, we do not believe that PAI-1 elevation is a consequence rather than a cause, of ulceration. It is unlikely to be caused by secondary infection, since the two groups of patients did not differ significantly in their C-reactive protein or fibrinogen concentrations. Therapeutic approaches aiming at returning PAI-1 activity to normal might therefore be helpful. Interestingly, beneficial effects of androgen therapy, which is known to reduce PAI-1 activity in healthy men, 15 have been recently reported. 7, 23 In our patients, androgen therapy was contraindicated due to underlying behavioural abnormalities.
